DPP-4 inhibitors × cardiovascular events

TrialDiabetes, obesity & metabolism2019

Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial.

Tianwei Gu et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 2019

Randomised comparison

Probably increased cardiovascular events

+38%+5% to +82%

Bigger than 6 in 10 for cardiovascular events

As reported

OR 1.38, 95% CI 1.05–1.82

One number in the abstract

the abstract, start to end

glimepiride (43.3% vs 31.3%; odds ratio, 1.38, 95% CI, 1.05-1.82; P = 0.019),

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
OR 1.381.05–1.82
MetforminDPP-4 inhibitorsSulfonylureas & glinidesCardiovascular events

DPP-4 inhibitors × cardiovascular eventshelps?replicated

unlikelylikely
0.990.50 without it

Metformin × cardiovascular eventshelps?mixed

unlikelylikely
0.500.50 without it

Sulfonylureas & glinides × cardiovascular eventshelps?replicated

unlikelylikely
0.960.50 without it
← favours comparatorfavours treatment →
this papermore certainless certain
1 / 5

4 papers cite it

2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 30520221